Director/PDMR Shareholding

By

Regulatory News | 09 May, 2023

Updated : 23:59

RNS Number : 8370Y
Omega Diagnostics Group PLC
09 May 2023
 


OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Director/PDMR Shareholding

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has received notification that Jag Grewal, Chief Executive Officer, and Chris Lea, Chief Financial Officer, each purchased 69,498 ordinary shares of 4 pence each in the Company ("Ordinary Shares") on 5 May 2023 through the Company's all-employee Share Incentive Plan, at a price of 2.59 pence each. At the same time, these individuals were also awarded (for no consideration) their corresponding Matching Shares under the plan.

 

A summary of each Directors resultant holdings is below:

 

 

Director

Board Position

Number of Partnership Shares acquired under the SIP on 5 May 2023

Number of Matching Shares acquired under the SIP on 5 May 2023

Total beneficial holding of Ordinary Shares following these acquisitions

Number of Ordinary Shares

Approximate % of Company's issued share capital

Jag Grewal

CEO

69,498

69,498

2,164,830

0.91%

Chris Lea

CFO

69,498

69,498

2,169,904

0.91%

 

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer






finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Alice Lane/Charlotte Sutcliffe (ECM)






Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258







 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Jag Grewal

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Omega Diagnostics Group PLC

b)

 

LEI

 

2138007U9P4BTZTYIR92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each

 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Ordinary Shares purchased

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

2.59 pence

69,498


d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

See above

e)

 

Date of the transaction

 

05.05.2023

f)

 

Place of the transaction

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Chris Lea

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Omega Diagnostics Group PLC

b)

 

LEI

 

2138007U9P4BTZTYIR92

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 4 pence each

 

 

 

 

ISIN: GB00B1VCP282

b)

 

Nature of the transaction

 

Ordinary Shares purchased

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

2.59 pence

69,498


d)

 

Aggregated information

 

 

-Aggregated volume

 

 

- Price

 

 

See above

e)

 

Date of the transaction

 

05.05.2023

f)

 

Place of the transaction

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDUDXGDGXC

Last news